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Introduction: Breast cancer is a worldwide health problem and the leading cause of cancer death among females.
We previously identified Jumonji domain containing 2A (JMJD2A) as a critical mediator of breast cancer proliferation,
migration and invasion. We now report that JMJD2A could promote breast cancer progression through transcriptional
repression of the tumor suppressor aplasia Ras homolog member I (ARHI).
Methods: Immunohistochemistry was performed to examine protein expressions in 155 cases of breast cancer and 30
non-neoplastic tissues. Spearman correlation analysis was used to analyze the correlation between JMJD2A expression
and clinical parameters as well as several tumor regulators in 155 cases of breast cancer. Gene and protein expressions
were monitored by quantitative polymerase chain reaction (qPCR) and Western blot. Results from knockdown of
JMJD2A, overexpression of JMJD2A, Co-immunoprecipitation (Co-IP) assay, dual luciferase reporter gene assay and
chromatin immunoprecipitation (ChIP) elucidated molecular mechanisms of JMJD2A action in breast cancer
progression. Furthermore, the effects of ARHI overexpression on JMJD2A-mediated tumor progression were
investigated in vitro and in vivo. For in vitro experiments, cell proliferation, wound-healing, migration and invasion
were monitored by cell counting, scratch and Boyden Chamber assays. For in vivo experiments, control cells and cells
stably expressing JMJD2A alone or together with ARHI were inoculated into mammary fat pads of mice. Tumor volume,
tumor weight and metastatic nodules were measured by caliper, electronic balance and nodule counting, respectively.
Results: JMJD2A was highly expressed in human breast cancers and positively correlated with tumor progression.
Knockdown of JMJD2A increased ARHI expression whereas overexpression of JMJD2A decreased ARHI expression at
both protein and mRNA levels. Furthermore, E2Fs and histone deacetylases were involved in the transcriptional
repression of ARHI expression by JMJD2A. And the aggressive behavior of JMJD2A in breast cancers could be reversed
by re-expression of ARHI in vitro and in vivo.
Conclusion: We demonstrated a cancer-promoting effect of JMJD2A and defined a novel molecular pathway contributing
to JMJD2A-mediated breast cancer progression.Introduction
Breast cancer is a worldwide health problem threatening
females. According to GLOBOCAN 2008 statistics, Breast
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reproduction in any medium, provided the ordeaths [1]. Multiple factors, including genetic background,
hormone disorder, and environmental impact are involved
in breast cancer pathogenesis [2]. Current evidence shows
that various genes contribute to breast cancer biological
behavior and clinical phenotypes. It is reported that breast
tumorigenesis is strongly associated with aberrant func-
tion of genes such as HER-2/neu, BRCA1 and CyclinD1
[3], which could be manipulated by gene expression level
and/or gene mutation/rearrangement. In fact, dysregula-
tion of gene expression, such as activation of oncogenes
or inactivation of tumor-suppressor genes, are frequentlyhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cidates that multiple gene mutations/rearrangements exist
in breast cancers [5,6]. Therefore, multiple genes are in-
volved in breast tumorigenesis. Further illustration of
breast cancer pathogenesis is critical for disease treatment
and prevention.
Recent discoveries of histone demethylases have ad-
vanced our understanding of transcriptional regulation
[7-9]. Histone demethylases are enzymes that catalyze
demethylation of lysine residues (mainly H3K4, H3K9,
H3K27, H3K36 and H4K20) located in the N-terminal
tails of histones. Based on recent findings, methylation
of H3K9, H3K27 and H4K20 is mainly associated with
repressive transcription whereas methylation of H3K4
and H3K36 mainly activates transcription [10]. Thus de-
methylation of different lysine residues may result in acti-
vated or repressed transcription. Jumonji domain containing
2A (JMJD2A, also known as JHDM3 or KDM4A) is a mem-
ber of JmjC domain containing family JMJD2 that catalyzes
histone demethylation. Due to its activity to demethylate di-
and tri-methylation on a variety of histone lysine residues,
such as H3K9 and H3K36 [11], H3K4 and H4K20 [12,13],
JMJD2A can modify chromatin structure and function as a
transcriptional repressor or activator. Previous report indi-
cated that JMJD2A significantly demethylates tri- and di-
methylated, but not monomethylated H3K36 and H3K9
in vivo [14]. Recent evidence shows that JMJD2A positively
regulates the expression of ADAM12,CXCL5 and JAG1 genes
through histone H3K9me3 demethylation [15]. Furthermore,
it was observed that H3K9me3 levels are increased at ASCL2
and CHD5 gene promoters after depletion of JMJD2A
[16,17]. JMJD2A is widely expressed in diverse cancers, in-
cluding lung carcinoma, colon cancer and breast cancer
[17-20]. In addition to its enzymatic activity, JMJD2A pro-
tein contains both leukemia-associated protein/plant home-
odomain (LAP/PHD) and Tudor domains which were
implicated protein-protein interactions. Functionally, JMJD2A
could interact with histone deacetylase (HDAC) and retino-
blastoma protein (pRb) and could direct repression of E2F-
responsive promoters [21]. JMJD2A is also reported to be a
novel N-CoR interacting protein, leading to transcriptional
repression of downstream genes like ASCL2 [16].
Aplasia Ras homolog member I (ARHI) is a Ras-related
small G-protein with a low guanosine triphosphate (GTP) en-
zymatic activity and Mg2+-dependence [22,23]. Unlike other
small GTP-binding proteins, ARHI exhibits functional repres-
sion of cell growth and functions as a tumor suppressor.
ARHI is highly expressed in normal breast and ovarian
tissues, but repressed in breast and ovarian cancers
[24,25], indicating that ARHI dysfunction is closely related
with tumorigenesis and progression. In fact, overexpres-
sion of ARHI leads to retarded proliferation [26,27], mi-
gration [28], and invasion [27,28] in breast cancer. ARHI
could restrict migration of non-cancer cells throughinteraction with C-RAF to suppress the activating phospho-
rylations on mitogen-activated protein kinase kinases (MEK)
and extracellular signal-regulated kinase (ERK). And knock-
down of ARHI could reverse the effect [29]. ARHI could also
suppress ovarian cancer cell migration through inhibition of
the Stat3 and FAK/Rho signaling pathways [30]. Like other
tumor suppressors, ARHI expression could be regulated by
deletion of an allele and promoter methylation [31], tran-
scriptional factors and HDAC-containing complexes [32,33].
E2F1 and E2F4 are reported to negatively regulate ARHI ex-
pression by forming complex with HDAC. Overexpression
of E2F1 and E2F4 could negatively regulate ARHI promoter
activity [33], and multiple HDACs such as HDAC1, 3 and 11
are identified to negatively regulate ARHI expression [32].
Previously, we reported that knockdown of JMJD2A
expression could slow down cell proliferation, migration
and invasion in both MCF-7 and MDA-MB-231 cells
[34,35]. However, the regulatory mechanisms remain un-
clear. In addition to ASCL2 gene, JMJD2A was shown to
transcriptionally repress other genes, such as the tumor
suppressor gene CHD5 in a lung carcinoma model [17].
In this study, we report that JMJD2A promotes breast
cancer progression through transcriptional repression of
the tumor suppressor ARHI. We found that JMJD2A
correlates with breast cancer progression and promotes
breast cancer progression through transcriptional silen-
cing of ARHI. The repression of ARHI expression by
JMJD2A required the involvements of E2Fs and HDACs,
and the aggressive behavior of JMJD2A could be reversed
by re-expression of ARHI both in vitro and in vivo. In all,
we defined a molecular pathway contributing to JMJD2A-
mediated breast cancer progression.
Materials and methods
Ethics statements
Permission to use human tissue sections for research
purposes was obtained and approved by an institutional
review board at Huashan Hospital, Shanghai, China. All
patients provided their full consent to participate in our
study. For animal research, the protocol was approved
by the Ethics Committee from Shanghai Medical College,
Fudan University, China. And all efforts were made to
minimize suffering.
Cells and reagents
Breast cancer cell lines MCF-7, T47D, SUM1315 and
MDA-MB-231 were purchased from ATCC (Manassas,
VA, USA) and cultured in DMEM (Hyclone, Logan,
Utah, USA) supplemented with 10% FBS (Gibco, Los
Angeles, CA, USA). Primary antibodies against JMJD2A
(C37E5), E2F1 (3742), HDAC1 (5356) and HDAC3
(3949) were purchased from Cell Signaling Technology
(Boston, MA, USA). Anti-estrogen receptor alpha (anti-
ERα) (ab2746), anti-progesterone receptor (PR)
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2 (anti-HER2) (ab134182), anti-E2F4 (ab150360) and anti-
ARHI (ab107051) primary antibodies were all obtained from
Abcam (Cambridge, UK). Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) antibody (sc-25778) was purchased
from Santa Cruz (CA, USA). Lipofectamine 2000 was pur-
chased from Invitrogen (Carlsbad, CA, USA). Trichosta-
tin A (TSA) was purchased from Sigma Co. (St Louis,
MO, USA). The chromatin immunoprecipitation (ChIP)
kit was purchased from Upstate (a part of Millipore, Bil-
lerica, MA, USA). For the co-immunoprecipitation
(Co-IP) assay, the protein G agarose beads and NP-40
lysis buffer were purchased from Beyotime Institute of
Biotechnology (Nantong, China). Matrigel was purchased
from BD Biosciences (San Jose, CA, USA). Cell count-
ing kit-8 (cck-8) was purchased from Dojindo (Japan).
And dual-luciferase reporter gene assay were from Pro-
mega (Madison, WI, USA).
Plasmids and siRNAs
JMJD2A expression plasmid was subscribed by Dr Ralf
Janknecht from the Department of Biochemistry and
Molecular Biology, Mayo Clinic College of Medicine
and Dr Hsing-Jien Kung, Deputy Director and Director
of Basic Science, UC Davis Cancer Center. JMJD2A
(NM_014663.2) was PCR-amplified from the subscribed
plasmids and cloned into pcDNA3.1 vetors (pcDNA3.1-
JMJD2A). ARHI (AY890085.1) was amplified on mRNA
from MCF-7 cells and cloned into pcDNA3.1 vetors
(pcDNA3.1-ARHI) as per the molecular cloning man-
ual. siRNA specific to JMJD2A was chemically synthe-
sized by Qiagen Technology Co. Ltd (Valencia, CA,
USA). siRNA was diluted to 20 μmol/L with RNase-free
water. siRNA duplexes were synthesized as follows: sense:
5′-GAGUUAUCAACUCAAGAUA-3′, antisense:5′-UAU
CUUGAGUUGAUAACUC-3′. The other two JMJD2A
siRNAs were synthesized by GenePharma (Shanghai,
China) with the sequences described previously [15].
siRNAs specific to E2F1 and E2F4 were also synthe-
sized by GenePharma (Shanghai, China) with sequences
verified and described previously [36,37]. Scramble siRNA
was used as negative control (NC) and sequences were as
follows: sense: UUCUCCGAACGUGUCACGU, antisense:
ACGUGACACGUUCGGAGAATT. Plasmids and siR-
NAs were transfected with Lipofectamine 2000 in ac-
cordance with the manufacturer’s instructions.
Patients and histological and immunohistochemical (IHC)
staining
All the 155 cases of breast cancer and 30 cases of non-
neoplastic tissues were retrieved from the Department of
Pathology, Huashan Hospital, Shanghai, China, within
2012. All cases were diagnosed by two experienced pa-
thologists without discrepancy. None of the patients hadreceived chemotherapy or radiation therapy previously.
The paraffin-embedded tissues were first stained with
hematoxylin and eosin (HE) for histological examination.
Subsequently, sections were subjected to antigen re-
trieval by heating the slides in a microwave at 100°C for
10 minutes in 0.1-M citric acid buffer (PH 6.0), and then
incubated with corresponding antibodies at 4°C over-
night. After secondary antibody incubation at room
temperature for 1 h, the slides were developed in 0.05%
diaminobenzidine containing 0.01% hydrogen peroxidase.
For negative controls, specific antibodies were replaced
with normal goat serum by co-incubation at 4°C overnight
preceding the immunohistochemiscal staining procedure.
Western blot analysis
At 48 h after transfection, cells in different treatment groups
were harvested. The procedure was used as described previ-
ously [38,39]. Antibodies against JMJD2A, ARHI, GAPDH,
E2F1, and E2F4 were used to incubate target proteins over-
night at 4°C. After the overnight incubation with the pri-
mary antibodies, membranes were washed and incubated
with horseradish peroxidase (HRP)-labeled secondary anti-
body in Tris-buffered saline with Tween 20 (TBST) for
1 h. Immunoreactivity was detected with enhanced che-
moluminescent autoradiography (ECL kit, Amersham,
Pittsburgh, PA, USA), according to the manufacturer’s in-
struction. GAPDH was used as a loading control.
Quantitative real-time PCR (qPCR)
Total RNA of each group were extracted respectively
using Trizol solution (Invitrogen) at 24 h after transfec-
tion. Fast-strand cDNA was generated from 1 μg of total
RNA using the PrimeScript RT Master Mix Perfect Real
Time (TaKaRa, Shiga, Japan). Real-time qPCR was per-
formed in an ABI PRISM 7500 Real-Time System. A 10-
fold dilution of each cDNA was amplified in a 50 μl
volume, using the SYBR Premix Ex TaqTM Perfect Real
Time (TaKaRa, Shiga, Japan). The primers used were as
follows: JMJD2A: forward 5′-ATCCCAGTGCTAGGAT
AATGACC-3′, reverse 5′-ACTCTTTTGGAGGAACCC




Primers were synthesized by Shanghai Daweike Bio-
technology Co. Ltd (Shanghai, China). PCR cycle condi-
tions were 95°C for 30 s, and 40 cycles of 95°C for 5 s
and 60°C for 34 s. The amplification specificity was eval-
uated with melting curve analysis. Relative mRNA was
determined by using the formula 2-ΔCT (CT, cycle
threshold) where, as described previously [40]:
ΔCT ¼ CT target geneð Þ − CT GAPDHð Þ:
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HEK293T cells were seeded at a density of 2 × 105/well
in 24-well plates and co-transfected with indicated amounts
of ARHI/luciferase reporter together with the full-length
JMJD2A construct (JMJD2A-FL), the construct of JMJD2A
with the substitution of histidine 188 by alanine (JMJD2A-
H188A), or another construct of JMJD2A with the deletion
of the tudor domains (JMJD2A-M867) [21,41]. Renilla lucif-
erase plasmid (pRL) was co-transfected as internal control.
Thirty-six hours after transfection, cells were lysed using
passive lysis buffer and assayed immediately for reporter and
control gene activities with the dual-luciferase reporter
gene assay using a Lumat LB 9507 luminometer (EG &
G Berthold, Bad Wildbad, Germany). To determine the
effect of HDACs, cells were treated with or without
100 nM trichostatin A (TSA) at 12 h after transfection.
Each experiment was performed in triplicate, and the
data represent three independent experiments after
normalization to renilla activity.
Chromatin immunoprecipitation (ChIP) assay
Briefly, lysates were incubated with 4 μg of anti-JMJD2A
antibody or normal rabbit IgG as a negative control.
PCR amplification was performed using 1:100 dilution of
input, an IgG negatively immunoprecipitated DNA and
specific JMJD2A immunoprecipitated DNA. In general,
samples were heated at 95°C for 3 minutes, followed by
31 cycles of 95°C for 30 s, 54°C for 30 s and 72°C for
20 s. After cycling, samples were incubated at 72°C for
10 minutes to permit completion of primers extension.
Then PCR products were electrophoresed on a 2%
agarose gel with ethidium bromide. The two pairs of
ARHI primers (A1, A2) were as follows: A1 (−181 to 91)
forward: 5′-TCGATTGTTGTAGATGCCAAG-3′, re-
verse: 5′-AGACTTACCTTTCTCGGAGGC-3′; A2 (−524
to −341), forward: 5′-TTTACCGGTCTTGCCACTAAT
G-3′, reverse: 5′-TCCAAAAGCAGTTTAATGCAGG-3′.
GAPDH was used as a loading control (154 bp).
Co-immunoprecipitation (Co-IP) assay
MDA-MB-231 cell lysates were obtained using NP-40
lysis buffer. Specific antibodies were used for immuno-
precipitation as well as 20 μl of protein G agarose beads.
The beads were washed in lysis buffer and boiled in
30 μl of SDS loading buffer; the entire sample was
loaded on a SDS-polyacrylamide gel and processed by
western blot. The membranes were immunoblotted with
corresponding primary antibodies. Rabbit normal IgG
was used as negative control.
CCK-8 proliferation assay
Cells were seeded on 96-well plates at an initial density
of 4 × 103/well. At each monitored time point, cells of
each well were stained with 10 μl CCK-8 (Dojindo,Japan) for 4 h at 37°C. Absorbance was measured using
a synergy 2 multi-mode microplate reader (Bio Tek In-
struments, Winooski, VT, USA) at 450 nm. All experi-
ments were carried out in triplicate.
Wound-healing assay and Boyden chamber assay
A wound-healing assay and Boyden chamber assay were
performed as described previously [42]. Cells were plated
on 6-well plates to form a confluent monolayer. Wounds
made with sterile pipette tips were observed per 12 h. A
migration assay was carried out using Boyden chambers
(tissue culture-treated, 6.5-mm diameter, 8-μm pores,
Transwell, Costar, Cambridge, MA, USA) containing
polycarbonate membrane. For the invasion assay, 50 μl
matrigel (BD Biosciences, San Jose, CA, USA) was used
to mimic basement membrane. Briefly, 100 μl of 1 × 106
cells in serum-free medium was added to the upper
chamber and 600 μl of appropriate medium with 10%
FBS was added to the lower chamber. Cells were incu-
bated for 12 h. Migration cells on the under-surface of
the membrane were fixed and stained with Giemsa for
10 minutes at room temperature. Photographs of five
random regions were taken and the number of cells was
counted to calculate the average number of migrated
cells per plate.
Mouse xenograft breast cancer models
Five-week-old female athymic nude mice (BALB/cnu/nu)
were used for the experiment. Cells stably expressing
JMJD2A or both JMJD2A and ARHI were constructed
as previously described [43]. Cells (1 × 106) were injected
subcutaneously into the mammary fat pad of the mice.
Mice were randomized (n = 7 per group) and assigned to
specific groups. Tumor diameters were measured twice
a week and tumor volumes (TV) were calculated using
the formula as described [44]:
TV ¼ LW2 =2:
On day 27 after tumor cell injection, the mice were
sacrificed and the excised tumors were measured and
weighed. Lung and liver metastatic nodules were also
calculated.
Statistical analysis
All values are expressed as mean ± SD. The Student’s t-test
and Spearman correlation analysis were used to evaluate
the experimental data. P <0.05 was considered statistically
significant.
Results
JMJD2A is highly expressed in breast cancer tissues
To investigate the role of JMJD2A in breast cancer, we ex-
amined JMJD2A expression in 155 human breast cancer
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examination was first carried out on non-neoplastic breast
tissues and breast cancer tissues, respectively (Figure 1A
and E). Then all the tissues were analyzed by immuno-
histochemistry using anti-JMJD2A antibody and graded
based on staining intensity (Figure 1B,C,F,G,H and I).
We found that JMJD2A protein mainly localized in the
nuclei and the positive rate in breast cancer tissues
(93%, 144/155, Figure 1D (b)) was significantly higher
than that in non-neoplastic tissues (3%, 1/30, Figure 1D
(a)) (P <0.001). Among 30 non-neoplastic tissues, only
one sample (3%) presented as weakly positive for
JMJD2A, whereas the other 29 samples (97%) were all
JMJD2A-negative. In contrast, 11 (7%) out of 155 cases
of breast cancer tissues were negative, 56 (36%) were
weakly positive, 53 (34%) were moderately positive and
35 (23%) were strongly positive. These data strongly
support that JMJD2A expression is significantly in-
creased in breast cancer tissues. Additionally, we ran-
domly selected two primary breast cancer tissues and
performed western blot analysis. This revealed that breast
cancer tissues displayed higher JMJD2A expression level
than that in paired tumor-adjacent non-cancerous tissues
in the two samples (Figure 2A). These results suggest that
JMJD2A is highly expressed in breast cancer.Figure 1 Immunohistochemistry (IHC) analysis of JMJD2A expression
(HE) staining of non-neoplastic tissues. (B, C) Representative results of the
protein in non-neoplastic tissues. (D) Distributions of JMJD2A staining g
breast cancer tissues (D, b). In non-neoplastic tissues, 29 out of 30 tissues
JMJD2A weakly positive. In breast cancer tissues, the positive rate of JMJD
than that in non-neoplastic tissues (3%) (P <0.001). (E) Validation of brea
negative staining (−, F), weakly positive staining (+, G), moderate stainin
cancer tissues are shown respectively. Scale bar = 20 μm.Expression of JMJD2A is positively correlated with
progression of breast cancer and negatively with tumor
suppressor ARHI
To determine whether the expression level of JMJD2A
was associated with progression of breast cancer, we ini-
tially examined JMJD2A expression in four breast cancer
cell lines, including two weakly metastatic cell lines
(MCF-7 and T47D) and two highly metastatic cell lines
(MDA-MB-231 and SUM1315). Compared with the
weakly metastatic cell lines, highly metastatic cell lines
had a higher expression level of JMJD2A (Figure 2B).
We then carried out Spearman correlation analysis to
determine the relationship between JMJD2A expres-
sion and clinical parameters (Table 1). Statistical ana-
lysis revealed that there was a significantly positive
correlation of JMJD2A expression with tumor, node,
metastasis (TNM) stage (P= 0.004, r= 0.227), and tumor size
(P= 0.026, r= 0.179), but JMJD2A expression did not signifi-
cantly correlate with lymph node metastasis (P= 0.102), or
with age (P= 0.092). These results reveal that JMJD2A posi-
tively relates to tumor progression.
We subsequently analyzed the relationship of JMJD2A
expression with tumor regulators including estrogen recep-
tor (ER)α, progesterone receptor (PR), HER2 and ARHI.
Our results showed that ERα and PR were stained mainlyin non-neoplastic and breast cancer tissues. (A) Hematoxylin-eosin
negative staining (B) and weakly positive staining (C) of JMJD2A
rades (−, +, ++ and +++) in both non-neoplastic tissues (D, a) and
exhibited to be JMJD2A negative and only 1 in 30 tissues exhibited to be
2A staining in breast cancer tissues (93%) was significantly higher
st cancer tissues by HE stain. (F, G, H, I) Representative results of
g (++, H) and strong staining (+++. I) of JMJD2A protein in breast
Figure 2 Expression level of JMJD2A in breast cancer
tissues and cell lines. (A) Western blot analysis of JMJD2A
protein from two random human primary breast cancer (T) and
paired tumor-adjacent non-cancerous breast tissues (N), with
each pair taken from the same patient. (B) Expression of JMJD2A protein
was detected in breast cancer cell lines. Extracts from two low-metastatic
breast cancer cell lines (MCF-7, T47D) and two highly metastatic breast
cancer cell lines (SUM1315 and MDA-MB-231) were subjected to western
blot analysis.
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brane (data not shown), whereas ARHI was mainly in the
cell membrane and partially in the cytoplasm (Figure 3B
and D). Spearman correlation analysis showed that ex-
pression of JMJD2A was inversely correlated with expres-
sion of ARHI (P = 0.016, r = −0.194, Table 2). However we
did not observe a significant association between JMJD2ATable 1 Association between JMJD2A expression and disease
Total
JM
0 (−) 1 (+)
n = 11 n = 56
TNM1 stage
I and II 139 10 54
III and IV 16 1 2
Tumor size
≤2 cm 110 6 48
2 cm < T ≤5 cm 42 5 7
>5 cm 3 0 1
Lymph node metastasis
Negative 100 9 29
Positive 55 2 27
Age
<50 years 46 4 21
≥50 years 109 7 35
1TNM stage is a classification of malignant tumors used by the International Federa
tumor, N describes nearby lymph nodes that are involved, and M describes distantimmunoreactivity and other tested clinicopathological pa-
rameters, including ERα (P = 0.778), PR (P = 0.147) and
HER2 (P = 0.742). This result implies that JMJD2A may be
negatively linked with the tumor suppressor ARHI.
To verify the negative relationship between JMJD2A
and ARHI, we firstly performed western blot analysis
using human breast cancer tissues and paired tumor-
adjacent non-cancerous tissues. As expected, ARHI was
downregulated in JMJD2A-overexpressed cancer tissues
and upregulated in tumor-adjacent tissues (Additional
file 1: Figure S1). We then carried out IHC staining on
serial sections with both anti-JMJD2A and ARHI anti-
bodies in non-neoplastic breast tissues and breast cancer
tissues. Our results showed that JMJD2A-negative stain-
ing sections were ARHI-positive both in non-neoplastic
tissues (Figure 3A and B) and cancer tissues (Figure 3C
and D), whereas ARHI-negative staining sections were
JMJD2A-positive in cancer tissues (Figure 3E and F).
Taken together, JMJD2A expression inversely correlated
with ARHI expression in both non-neoplastic tissues and
breast cancer tissues.
JMJD2A binds to ARHI promoter and negatively controls
its promoter activity
To further investigate the role of JMJD2A in ARHI ex-
pression, we carried out western blot analysis in vitro
with weakly-metastatic cell line MCF-7 and highly meta-
static cell line MDA-MB-231. siRNA specific against
JMJD2A (siRNA group) and JMJD2A expression plas-
mid (pcDNA3.1-JMJD2A (JMJD2A)) were transfected
into both cell lines. Transfection efficiency was approxi-
mately 71.3% (data not shown). Our results showed thatparameters in 155 cases of breast cancer
JD2A
P -value Correlationcoefficient2 (++) 3 (+++)
n = 53 n = 35











tion of Gynecology and Obstetrics (FIGO). T describes the size of primary
metastasis. *P <0.05, **P <0.01.
Figure 3 JMJD2A is negatively correlated with Aplasia Ras homolog member I (ARHI) in breast tissues. Serial sections were stained with
JMJD2A and ARHI antibodies, respectively. (A) Representative result of negative JMJD2A staining in serial sections from non-neoplastic tissues.
(B) Representative result of positive ARHI staining in serial sections from non-neoplastic tissues. (C) Representative result of negative JMJD2A
staining in serial sections from breast cancer tissues. (D) Representative result of positive ARHI staining in serial sections from breast cancer
tissues. (E) Representative result of positive JMJD2A staining in serial sections from breast cancer tissues. (F) Representative result of negative
ARHI staining in serial sections from breast cancer tissues. Scale bar = 20 μm.
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crease in ARHI expression whereas overexpression of
JMJD2A led to a decrease in ARHI expression both in
MDA-MB-231 cells (Figure 4A) andMCF-7 cells (Figure 4C).
Two additional siRNAs against JMJD2A also elucidated the
negative relationship between JMJD2A and ARHI expression
at protein level (Additional file 2: Figure S2). Consistently,
real-time qPCR analyses indicated that mRNA of ARHI was
elevated in the siRNA group and reduced in the JMJD2ATable 2 Association between JMJD2A expression and clinicop
Total
JMJD2A
0 (−) 1 (+)
n = 11 n = 56
ERα
Negative 52 4 18
Positive 103 7 38
PR
Negative 77 7 22
Positive 78 4 34
HER2
Negative 7 0 3
Positive 148 11 53
ARHI
Negative 63 20 12
Positive 92 40 24
*P <0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermalgroup (Figure 4B and D), suggesting that JMJD2A negatively
regulated ARHI expression at transcriptional level. Recent
evidence shows that JMJD2A could interact with HDACs
and pRb [21], and E2F-HDAC complex functions as a tran-
scriptional repressor of ARHI [33]. In fact, two binding sites
of transcription factors at the ARHI promoter were reported
including the site bound by E2Fs (from −524 to −341, indi-
cated as the A2 site) and another site directly or indirectly
bound by HDACs (from −181 to 91, indicated as the A1 site)athological parameters in 155 cases of breast cancer
P-value Correlationcoefficient2 (++) 3 (+++)













growth factor receptor-2; ARHI, Aplasia Ras homolog member I.
Figure 4 JMJD2A binds to ARHI gene promoter and represses ARHI transcriptional activity. (A, B) Western blot and quantitative real-time
PCR (qPCR) analysis of expressions of JMJD2A and ARHI in breast cancer cell line MDA-MB-231. siRNA against JMJD2A and JMJD2A expression
plasmid were used, respectively. ARHI expression level was upregulated in the siRNA group and downregulated in the JMJD2A group. (C, D) Western
blot and qPCR analysis of expressions of JMJD2A and ARHI in breast cancer cell line MCF-7. The results were proved similar to those in breast cancer
cell line MDA-MB-231. (E) JMJD2A binds to the ARHI gene promoter with two binding sites (A1 and A2). Anti-JMJD2A antibody was adopted. Normal
IgG was used as negative control. The A1 site is critical for histone deacetylase (HDAC) binding with the ARHI promoter while A2 for E2Fs binding with
ARHI promoter. GAPDH was used as a loading control. Two binding sites were both verified. *P <0.05, **P <0.01. ARHI, Aplasia Ras homolog member I;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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http://breast-cancer-research.com/content/16/3/R56[32,33]. Thus we hypothesized that JMJD2A might bind to
the ARHI promoter by interaction with E2Fs (mainly E2F1
and E2F4) and HDACs (mainly HDAC1 and HDAC3). We
first assessed whether JMJD2A could immunoprecipitate the
ARHI promoter. DNA immunoprecipitated by antibodies
was then amplified by PCR with two pairs of primers specific
for the respective binding sites. As expected, no DNA frag-
ment was detected when normal IgG was used. In contrast,
DNA fragments immunoprecipitated by JMJD2A antibody
yielded a 183-base product that spanned nucleotides (−524
to −341) (Figure 4E), suggesting that JMJD2A could directly
or indirectly bind to the binding site of E2Fs. Moreover, we
could also amplify the DNA fragment (−181 to 91) to
observe a 270-base product (Figure 4E), suggesting
that JMJD2A might form a complex with HDACs and/
or other transcription factors. Therefore, JMJD2A could
bind to the promoter of ARHI to inhibit the expression of
ARHI.
E2Fs and HDACs are involved in JMJD2A binding to the
ARHI promoter
To uncover the detailed mechanism of JMJD2A binding to
the ARHI promoter, we first investigated the interactions
of JMJD2A, E2Fs and HDACs. As shown in Figure 5A,
JMJD2A specifically co-immunoprecipitated E2F1, E2F4,HDAC1 and HDAC3. In fact, HDAC1 and HDAC3 were
previously reported to immunoprecipitate JMJD2A [21].
E2F1 and E2F4, respectively, also immunoprecipitated
JMJD2A (Figure 5B and C), suggesting that E2Fs and
HDACs could form a complex with JMJD2A. We then
synthesized specific siRNAs against E2F1 and E2F4 to
determine whether E2Fs are required for JMJD2A binding
to the ARHI promoter. Two siRNAs were proved to work
efficiently (Figure 6A). Subsequent ChIP assay showed
that band density was lower when either siE2F1 or siE2F4
was transfected. And after co-transfection of both siRNAs,
band density was further decreased (Figure 6B), suggesting
that JMJD2A binding with the A2 site (−524 to −341)
in the ARHI promoter required the involvements of
E2Fs. Tudor domain of JMJD2A is critical for protein
interaction and the JmjC domain is pivotal for enzymatic
activity. We constructed two mutants of JMJD2A expres-
sion plasmid, namely JMJD2A-M867 and JMJD2A-H188A,
respectively and performed a dual luciferase reporter assay.
Our results showed that JMJD2A-H188A could inhibit the
ARHI promoter activity as did by JMJD2A-FL whereas
JMJD2A-M867 partially lost the inhibition effect (Figure 6C),
indicating that the Tudor domains, but not the catalytic
activity, of JMJD2A might be required for JMJD2A-
mediated repression of promoter activity. Furthermore,
Figure 5 Interactions between JMJD2A, E2F1, E2F4, histone deacetylase (HDAC)1 and HDAC3. (A) JMJD2A could immunoprecipitate E2F1,
E2F4, HDAC1 and HDAC3. (B) JMJD2A could be immunoprecipitated by E2F1 with anti-E2F1 antibody. (C) JMJD2A could be immunoprecipitated
by E2F4 with anti-E2F4 antibody. IP, immunoprecipation; Ab, antibody.
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ition of the ARHI promoter activity, corroborating the
conclusion that JMJD2A-mediated repression requires
HDACs. Overall, JMJD2A binding to the ARHI pro-
moter requires the involvement of E2Fs and HDACs.
ARHI reverses JMJD2A-induced tumor progression in vitro
and in vivo
To reinforce the link between ARHI and JMJD2A, we inves-
tigated the role of ARHI during JMJD2A overexpression-
mediated tumor progression. To this end, the inhibitory
effects of ARHI on cell proliferation, migration, and inva-
sion were first confirmed in vitro and in vivo (Additional
file 3: Figure S3). Next, cell proliferation was detected in
MCF-7 cells and MDA-MB-231 cells transfected with
JMJD2A alone or along with ARHI. We found that
ARHI significantly suppressed JMJD2A-induced tumor
cell hyper-proliferation (Figure 7A and E). The prolif-
erative rate was dampened by approximately 40% in
MDA-MB-231 cells and 33% in MCF-7 cells on day 4,Figure 6 E2F and histone deacetylase (HDAC) are involved in the tran
against E2F1 and E2F4 were efficient to knockdown E2F1 and E2F4 express
site of the ARHI promoter. Both siRNAs could inhibit the binding of JMJD2A
(H188A and M867) and trichostatin A (TSA) on ARHI promoter activity. *P <when ARHI was co-transfected. The wound-healing
assay also showed that JMJD2A-mediated motility was
inhibited by overexpression of ARHI (Figure 7B and F).
Similarly, compared with the JMJD2A group, both
migration and invasion abilities were also reduced after
co-transfection of JMJD2A and ARHI plasmids (Figure 7C
and G). In the migration assay, ARHI reduced migratory
cells by 43.5% in MDA-MB-231 cells (Figure 7D) and
18.5% in MCF-7 cells (Figure 7H) compared with the
JMJD2A group. In the invasion assay, ARHI decreased
invasive cells by 47.8% in MDA-MB-231 cells (Figure 7D)
and 30.8% in MCF-7 cells (Figure 7H) compared with the
JMJD2A group.
To further investigate the role of ARHI on JMJD2A-
induced tumorigenesis in vivo, we used a female athymic
mice model of breast cancer. Tumor diameters were mea-
sured regularly to calculate tumor volumes (Figure 8A).
Volume measurement showed that tumors displayed a
smaller size in volume in each monitored time point when
ARHI was co-transfected (Figure 8A). Tumors werescriptional inhibition of ARHI by JMJD2A. (A) Specific siRNAs
ion level. (B) Effects of E2Fs knockdown on JMJD2A binding to the A2
to the ARHI promoter. (C) Effects of JMJD2A-FL, JMJD2A mutants
0.05, **P <0.01. ARHI, Aplasia Ras homolog member I.
Figure 7 ARHI reverses JMJD2A-induced tumor progression in vitro. MDA-MB-231 cells and MCF-7 cells were transfected with empty vetor,
pcDNA3.1-JMJD2A plasmid, and pcDNA3.1-JMJD2A&pcDNA3.1-ARHI plasmids in advance. (A, E) ARHI reversed JMJD2A-mediated cell proliferation
by day 2 and inhibited JMJD2A-mediated proliferation by up to 40% in MDA-MB-231 cells (A) and 33% in MCF-7 cells (E) on day 4. (B, F) Two cell
lines were analyzed using a wound-healing assay. Motility was compared between different groups. At 24 h ARHI slowed down JMJD2A-promoted
motility in MDA-MB-231 cells (B). At 36 h ARHI slowed down JMJD2A-promoted motility in MCF-7 cells (F); magnification 200×. (C, G) A transwell assay
was performed on MDA-MB-231 cells (C) and MCF-7 cells (G). ARHI was observed to attenuate JMJD2A-promoted migration and invasion ability; scale
bar = 20 μm. (D, H) The transwell assay was photographed and migrated/invaded cell numbers of five random regions were counted to calculate the
average number of cells that transmigrated. *P <0.05, **P <0.01. ARHI, Aplasia Ras homolog member I.
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Consistently, compared with the average weight when
JMJD2A was overexpressed alone, a lower mass in weight
was also observed when ARHI was overexpressed together
with JMJD2A (Figure 8B and C). Actually, compared with
JMJD2A group, tumor growth was slowed down by nearly
50% on day 27 when ARHI expression plasmid wastransfected along with JMJD2A expression plasmid
(Figure 8C). During dissection, we observed meta-
static nodules in lung and liver. Nodules in each group of
mice were counted to calculate average nodule numbers.
Our results showed that average metastatic nodules in liver
in each group were significantly different (Figure 8D,
*P <0.05 versus the JMJD2A group). This was in accordance
Figure 8 ARHI reverses JMJD2A-induced tumor progression in vivo in a xenograft model. MDA-MB-231 cells stably expressing JMJD2A
alone or along with ARHI were constructed. Cells treated with empty vetor were used as control. (A) Periodic detection of tumor volume in three
groups. (B) Tumors were dissected and each tumor in three groups was exhibited. (C) Tumors excised were weighed on day 27. (D) Breast cancer
metastasis was observed and liver nodules were counted in three groups. Total nodule numbers were statistically analyzed. *P <0.05, **P <0.01.
ARHI, Aplasia Ras homolog member I.
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overexpression-induced tumor migration and invasion
in vitro. However, we did not observe a significant dif-
ference in the average number of metastatic nodules in
lung (data not shown). In all, ARHI could invert JMJD2A-
induced tumor progression.
Discussion
JMJD2A is involved in diverse cancers, including lung car-
cinoma [17], colon cancer [19] and breast cancer [18,20].
We previously found that mRNA level of JMJD2A is nega-
tively correlated to that of the tumor suppressor ARHI
in breast cancer [20]. Here, we demonstrated a breast
cancer-promoting effect of JMJD2A and the regulatory
mechanism of ARHI expression by JMJD2A.
Recently, numerous HDAC-containing repression com-
plexes have been identified [32,33,45-49]. Among them,
E2F-HDAC repressor is characterized as an important
one. Here we demonstrated that transcriptional repression
of ARHI by JMJD2A requires the involvement of E2F and
HDAC. ARHI was downregulated by JMJD2A at bothprotein and mRNA level. And ARHI promoter activity
was significantly inhibited by JMJD2A, indicating a tran-
scriptional repression of ARHI by JMJD2A. Current evi-
dence shows that JMJD2A could interact with HDAC
(mainly HDAC1 and HDAC3) and pRb [21]. E2F1 and
E2F4 could mediate repression of ARHI promoter activity
on the identified binding site (A2: −524 to −341) together
with HDAC and/or pRb, respectively [33]. ChIP assay
suggested that JMJD2A could immunoprecipitate the
A2 site of the ARHI promoter (Figure 4E). Co-IP assay
revealed the interactions of JMJD2A with E2F1, E2F4,
HDAC1 and HDAC3 (Figure 5A). Furthermore, knock-
down of E2F1 and/or E2F4 significantly suppressed the
recruitment of JMJD2A to the A2 site in the ARHI pro-
moter (Figure 6B). Therefore, JMJD2A could form a com-
plex with E2Fs and HDACs to repress the ARHI promoter
activity. Additionally, multiple HDACs (mainly HDAC1
and HDAC3) are also reported to directly or indirectly bind
to the ARHI promoter at the site from −181 to 91 (A1)
[32]. Inhibition of HDAC activity by TSA treatment signifi-
cantly increased ARHI promoter activity (Figure 6C).
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quence, only transcription factors like Sp1 and PEA3
were specifically predicted to bind ARHI promoter site
from −181 to 91 [50]. HDAC could not specifically bind
to the A1 site in the ARHI promoter. We speculate that
there might be other transcription factors such as Sp1,
PEA3 which forms a complex with JMJD2A and
HDACs at the A1 site. Collectively, binding of JMJD2A
to the ARHI promoter is E2F- and HDAC-dependent.
Moreover, ARHI re-expression reversed JMJD2A-induced
tumor progression in vitro (Figure 7) and in vivo (Figure 8),
which in turn corroborated our results that JMJD2A
promotes breast cancer progression through transcrip-
tional repression of the tumor suppressor ARHI. Taken
together, we defined a novel gene regulated by JMJD2A
in breast cancer.
Intriguingly, ERα was not observed to significantly cor-
relate with JMJD2A (P = 0.778). As a member of the
same family, JMJD2B was reported to interact with ERα
and SWI/SNF-B complex upon estrogen stimulation and
lead to ERα target genes activation [51]. In this process,
JmjC catalytical domain, a structure harbored by both
JMJD2A and JMJD2B, is crucially required. Thus, JMJD2A
was thought to participate in breast cancer onset through
the ERα signaling pathway. However, the report further
showed that depletion of JMJD2A caused only a marginal
defect in ERα target gene induction, indicating that
JMJD2A interaction with ERα was not robust. These
results are in line with our findings.
The identification of ARHI as a gene regulated by JMJD2A
is of biological significance. JMJD2A was reported to tran-
scriptionally repress ASCL2 in vitro [16,17] and CHD5 in
lung carcinoma [17]. Genes regulated by JMJD2A in breast
cancer have not been reported. Our report may extend the
list of downstream genes regulated by JMJD2A. Moreover,
the tumor suppressor ARHI is frequently downregulated in
breast cancers [22-25]. Here we further demonstrated the
regulatory network contributing to ARHI inactivation in
breast cancers.
The effect of chromatin structure on gene transcrip-
tion is determined, at least in part, by the posttranscrip-
tional modifications of the histones, such as acetylation
and methylation [52]. Acetylation is believed to facilitate
transcription whereas deacetylation reverses such effects
and thus, reinforces the repressive effect of chromatin
[52]. As histone deacetylase, HDAC possibly plays key
roles in the repression of transcription. Our results showed
that inhibition of ARHI promoter activity by JMJD2A re-
quired the involvement of HDAC. In fact, HDAC has func-
tional links to histone acetylation and mediates ARHI
repression [32]. In contrast, histone demethylation might
not be required. Similar to JMJD2A-FL, JMJD2A-H188A
could also repress ARHI promoter activity. Moreover,
JMJD2A contains LAP/PHD and Tudor domains, whichare implicated in protein-protein interactions [21]. In this
way, JMJD2A could recruit co-regulators, such as pRb, E2F
and HDAC. Actually, deletion of Tudor domains impaired
JMJD2A-mediated repression of ARHI promoter activity
(Figure 6C). It is possible that JMJD2A loses the ability to
bind to promoters or to recruit the regulatory factors after
deletion of the Tudor domains.
One interesting observation is the significant liver in-
stead of lung metastasis in the xenograft model. Metasta-
sis is common in malignant tumors. The liver represents a
common site of metastasis for solid cancers and the third
most common site for breast cancer metastasis [53]. The
metastatic cascade consists of numerous steps, in which
interactions between primary tumor cells and resident
cells represent the most important factors determining to
which organs tumors metastasize [54,55]. The importance
of cancer cell-hepatocyte interactions was reinforced by
the observation that colorectal cancer cells also interact
with hepatocytes when metastasizing to liver [56,57]. As
adhesion molecules such as claudin-2 are reported to pro-
mote breast cancer liver metastasis by facilitating tumor
cell interactions with hepatocytes [58,59], we speculate
that there must be other molecules regulated by JMJD2A
that mediate breast cancer preferably liver metastasis.
Further studies will be required to understand the
mechanism.
Collectively, JMJD2A promotes breast cancer progres-
sion through transcriptional repression of the tumor
suppressor ARHI. Of note, JMJD2A was predicted to be
a transcriptional repressor and activator [17]. Here we
elucidate JMJD2A as a transcriptional repressor of tumor
suppressor ARHI. Genes transcriptionally activated by
JMJD2A in breast cancer may also potentially exist. Other
genes repressed/activated by JMJD2A in breast cancer re-
main to be exploited.Conclusion
In summary, our data indicate that JMJD2A could pro-
mote breast cancer progression through transcriptional
repression of the tumor suppressor ARHI. In the clinic,
JMJD2A associates with tumor progression. JMJD2A
could also promote breast cancer cell proliferation, in-
vasion and migration which could be reversed by ARHI
re-expression. The repression of ARHI expression by
JMJD2A requires the involvements of E2Fs and HDACs.Additional files
Additional file 1: Figure S1. JMJD2A is negatively correlated with
Aplasia Ras homolog member I (ARHI) expression in breast cancer tissues.
Western blot analysis of both JMJD2A and ARHI expression levels in two
random human primary breast cancer (T) and paired tumor-adjacent
non-cancerous breast tissues (N), with each pair taken from the same
patient.
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http://breast-cancer-research.com/content/16/3/R56Additional file 2: Figure S2. Knockdown of JMJD2A could upregulate
Aplasia Ras homolog member I (ARHI) expression. Two additional specific
siRNAs against JMJD2A were synthesized and transfected, respectively.
Negative control siRNA was also used. Both JMJD2A and ARHI expression
were detected with western blot analysis. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as loading control.
Additional file 3: Figure S3. Aplasia Ras homolog member I (ARHI)
inhibits the tumor progression in vitro and in vivo. MDA-MB-231 cells
with (ARHI) or without (Control) stable expressions of ARHI were
generated using the Lenti-X system (Clontech). Analysis of cell proliferation
(A), migration (wound-healing assay, B) and invasion (C) were performed.
(D) The in vivo effect of ARHI was evaluated in the mouse xenograft
model and the tumor weight was calculated on day 25 (n = 6 for each
group). *P <0.05.
Abbreviations
ARHI: Aplasia Ras homolog member I; ASCL2: Achaete scute-like homologue
2; bp: base pairs; CHD5: Chromodomain helicase DNA-binding protein 5;
ChIP: chromatin immunoprecipitation; Co-IP: co-immunoprecipitation;
CT: cycle threshold; DMEM: Dulbecco’s modified Eagle’s medium;
ERα: Estrogen receptor alpha; FBS: fetal bovine serum;
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; HDAC: Histone
deacetylase; HE: hematoxylin and eosin; HER2: Human epidermal growth
factor receptor-2; IHC: immunohistochemistry; JMJD2A: Jumoji domain
containing 2A; PR: Progesterone receptor; qPCR: quantitative real-time PCR;
TSA: trichostatin A.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LLL and AMX performed the western blot, qPCR, proliferation assay,
wound-healing assay and Boyden chamber assay and drafted the whole
manuscript. BXL and YWS contributed to the ChIP assay, Co-IP assay and
statistical analysis. CLL and YHL carried out the in vivo studies. MCZ, JQJ
and ZDX prepared tissue sections and participated in IHC analysis. JHX
designed the whole study and carried out the dual luciferase reporter
assay. ZQZ conceived of the study and revised the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by the national science foundation of China
(number 81172897). We thank Dr Ralf Janknecht and Dr Hsing-Jien Kung for
JMJD2A expression plasmids.
Author details
1Department of Forensic Medicine, School of Basic Medical Sciences, Fudan
University, 138 Yixueyuan Road, Xuhui district, Shanghai 200032, P. R. China.
2Department of Pathology, School of Basic Medical Sciences, Fudan
University, 138 Yixueyuan Road, Xuhui district, Shanghai 200032, P. R. China.
Received: 3 July 2013 Accepted: 22 May 2014
Published: 30 May 2014
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Meads C, Ahmed I, Riley RD: A systematic review of breast cancer
incidence risk prediction models with meta-analysis of their performance.
Breast Cancer Res Treat 2012, 132:365–377.
3. Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA, Benitez J: The
molecular pathology of hereditary breast cancer. Pathobiology 2008,
75:85–94.
4. Lee EY, Muller WJ: Oncogenes and tumor suppressor genes. Cold Spring
Harb Perspect Biol 2010, 2:a3236.
5. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM,
Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-
Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J,
Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V,
Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL,Schumacher SE, Stransky N, et al: Sequence analysis of mutations and
translocations across breast cancer subtypes. Nature 2012, 486:405–409.
6. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC,
Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E,
Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A,
Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L,
Raine K, Rad R, Chapman MS, Teague J, et al: The landscape of cancer
genes and mutational processes in breast cancer. Nature 2012,
486:400–404.
7. Klose RJ, Zhang Y: Regulation of histone methylation by demethylimination
and demethylation. Nat Rev Mol Cell Biol 2007, 8:307–318.
8. Mosammaparast N, Shi Y: Reversal of histone methylation: biochemical
and molecular mechanisms of histone demethylases. Annu Rev Biochem
2010, 79:155–179.
9. Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J,
Zhang Y: JHDM2A, a JmjC-containing H3K9 demethylase, facilitates
transcription activation by androgen receptor. Cell 2006, 125:483–495.
10. Peterson CL, Laniel MA: Histones and histone modifications. Curr Biol 2004,
14:R546–R551.
11. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P,
Wong J, Zhang Y: The transcriptional repressor JHDM3A demethylates
trimethyl histone H3 lysine 9 and lysine 36. Nature 2006, 442:312–316.
12. Huang Y, Fang J, Bedford MT, Zhang Y, Xu RM: Recognition of histone H3
lysine-4 methylation by the double tudor domain of JMJD2A. Science
2006, 312:748–751.
13. Lee J, Thompson JR, Botuyan MV, Mer G: Distinct binding modes specify
the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor.
Nat Struct Mol Biol 2008, 15:109–111.
14. Shin S, Janknecht R: Diversity within the JMJD2 histone demethylase
family. Biochem Biophys Res Commun 2007, 353:973–977.
15. Kogure M, Takawa M, Cho HS, Toyokawa G, Hayashi K, Tsunoda T, Kobayashi
T, Daigo Y, Sugiyama M, Atomi Y, Nakamura Y, Hamamoto R: Deregulation
of the histone demethylase JMJD2A is involved in human
carcinogenesis through regulation of the G1/S transition. Cancer Lett
2013, 336:76–84.
16. Zhang D, Yoon HG, Wong J: JMJD2A is a novel N-CoR-interacting protein
and is involved in repression of the human transcription factor achaete
scute-like homologue 2 (ASCL2/Hash2). Mol Cell Biol 2005, 25:6404–6414.
17. Mallette FA, Richard S: JMJD2A promotes cellular transformation by
blocking cellular senescence through transcriptional repression of the
tumor suppressor CHD5. Cell Rep 2012, 2:1233–1243.
18. Berry WL, Shin S, Lightfoot SA, Janknecht R: Oncogenic features of the
JMJD2A histone demethylase in breast cancer. Int J Oncol 2012, 41:1701–1706.
19. Kim TD, Shin S, Berry WL, Oh S, Janknecht R: The JMJD2A demethylase
regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem
2012, 113:1368–1376.
20. Li BX, Li J, Luo CL, Zhang MC, Li H, Li LL, Xu HF, Shen YW, Xue AM, Zhao
ZQ: Expression of JMJD2A in infiltrating duct carcinoma was markedly
higher than fibroadenoma, and associated with expression of ARHI, p53
and ER in infiltrating duct carcinoma. Indian J Exp Biol 2013, 51:208–217.
21. Gray SG, Iglesias AH, Lizcano F, Villanueva R, Camelo S, Jingu H, Teh BT,
Koibuchi N, Chin WW, Kokkotou E, Dangond F: Functional characterization
of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.
J Biol Chem 2005, 280:28507–28518.
22. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC: ARHI is
a Ras-related small G-protein with a novel N-terminal extension that inhibits
growth of ovarian and breast cancers. Oncogene 2003, 22:2897–2909.
23. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW,
Siciliano M, Mills GB, Bast RJ: NOEY2 (ARHI), an imprinted putative tumor
suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S
A 1999, 96:214–219.
24. Hisatomi H, Nagao K, Wakita K, Kohno N: ARHI/NOEY2 inactivation may
be important in breast tumor pathogenesis. Oncology-Basel 2002,
62:136–140.
25. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA,
Lippman SM, Bast RJ, Yu Y: Loss of the expression of the tumor
suppressor gene ARHI is associated with progression of breast cancer.
Clin Cancer Res 2003, 9:3660–3666.
26. Janssen EA, Ovestad IT, Skaland I, Soiland H, Gudlaugsson E, Kjellevold KH,
Nysted A, Soreide JA, Baak JP: LOH at 1p31 (ARHI) and proliferation in
lymph node-negative breast cancer. Cell Oncol 2009, 31:335–343.
Li et al. Breast Cancer Research 2014, 16:R56 Page 14 of 14
http://breast-cancer-research.com/content/16/3/R5627. Li Y, Liu M, Zhang Y, Han C, You J, Yang J, Cao C, Jiao S: Effects of ARHI on
breast cancer cell biological behavior regulated by microRNA-221.
Tumour Biol 2013, 34:3545–3554.
28. Yu Y, Luo R, Lu Z, Wei FW, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RJ:
Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor
suppressor gene whose expression is lost in ovarian and breast cancers.
Methods Enzymol 2006, 407:455–468.
29. Klingauf M, Beck M, Berge U, Turgay Y, Heinzer S, Horvath P, Kroschewski R:
The tumour suppressor DiRas3 interacts with C-RAF and downregulates
MEK activity to restrict cell migration. Biol Cell 2013, 105:91–107.
30. Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M,
Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RJ: The tumor-suppressor gene
ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition
of the Stat3 and FAK/Rho signaling pathways. Oncogene 2012, 31:68–79.
31. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RJ:
Imprinted tumor suppressor genes ARHI and PEG3 are the most
frequently down-regulated in human ovarian cancers by loss of
heterozygosity and promoter methylation. Cancer 2008, 112:1489–1502.
32. Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS, Yu Y: Multiple histone
deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J
Cancer 2007, 120:1664–1668.
33. Lu Z, Luo RZ, Peng H, Huang M, Nishmoto A, Hunt KK, Helin K, Liao WS, Yu Y:
E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI
in breast cancer. Oncogene 2006, 25:230–239.
34. Li BX, Luo CL, Li H, Yang P, Zhang MC, Xu HM, Xu HF, Shen YW, Xue AM,
Zhao ZQ: Effects of siRNA-mediated knockdown of jumonji domain
containing 2A on proliferation, migration and invasion of the human
breast cancer cell line MCF-7. Exp Ther Med 2012, 4:755–761.
35. Li BX, Zhang MC, Luo CL, Yang P, Li H, Xu HM, Xu HF, Shen YW, Xue AM,
Zhao ZQ: Effects of RNA interference-mediated gene silencing of JMJD2A
on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer
Res 2011, 30:90.
36. Guo R, Chen J, Mitchell DL, Johnson DG: GCN5 and E2F1 stimulate
nucleotide excision repair by promoting H3K9 acetylation at sites of
damage. Nucleic Acids Res 2011, 39:1390–1397.
37. DuPree EL, Mazumder S, Almasan A: Genotoxic stress induces expression
of E2F4, leading to its association with p130 in prostate carcinoma cells.
Cancer Res 2004, 64:4390–4393.
38. Luo CL, Chen XP, Li LL, Li QQ, Li BX, Xue AM, Xu HF, Dai DK, Shen YW, Tao LY,
Zhao ZQ: Poloxamer 188 Attenuates in vitro Traumatic Brain Injury-Induced
Mitochondrial and Lysosomal Membrane Permeabilization Damage in
Cultured Primary Neurons. J Neurotrauma 2013, 30:597–607.
39. Wang Y, Han R, Liang ZQ, Wu JC, Zhang XD, Gu ZL, Qin ZH: An autophagic
mechanism is involved in apoptotic death of rat striatal neurons
induced by the non-N-methyl-D-aspartate receptor agonist kainic acid.
Autophagy 2008, 4:214–226.
40. Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I,
Jones M, Ottewell PD: Loss of plakoglobin promotes decreased cell-cell
contact, increased invasion, and breast cancer cell dissemination in vivo.
Breast Cancer Res 2012, 14:R86.
41. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li
E, Zhang G, Colaiacovo M, Shi Y: Reversal of histone lysine trimethylation
by the JMJD2 family of histone demethylases. Cell 2006, 125:467–481.
42. Cheng C, Kong X, Wang H, Gan H, Hao Y, Zou W, Wu J, Chi Y, Yang J, Hong Y,
Chen K, Gu J: Trihydrophobin 1 Interacts with PAK1 and Regulates ERK/
MAPK Activation and Cell Migration. J Biol Chem 2009, 284:8786–8796.
43. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu
ET, Desai KV: JMJD6 is a driver of cellular proliferation and motility and a
marker of poor prognosis in breast cancer. Breast Cancer Res 2012, 14:R85.
44. Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RJ, Feng Y, Yu Y:
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer
cells and enhances the inhibitory effect of paclitaxel. BMC Cancer
2011, 11:22.
45. Blander G, Guarente L: The Sir2 family of protein deacetylases. Annu Rev
Biochem 2004, 73:417–435.
46. Bowen NJ, Fujita N, Kajita M, Wade PA: Mi-2/NuRD: multiple complexes for
many purposes. Biochim Biophys Acta 2004, 1677:52–57.
47. Feng Q, Zhang Y: The NuRD complex: linking histone modification to
nucleosome remodeling. Curr Top Microbiol Immunol 2003, 274:269–290.
48. Glass CK, Rosenfeld MG: The coregulator exchange in transcriptional
functions of nuclear receptors. Genes Dev 2000, 14:121–141.49. Wolffe AP, Urnov FD, Guschin D: Co-repressor complexes and remodelling
chromatin for repression. Biochem Soc Trans 2000, 28:379–386.
50. Luo RZ, Peng H, Xu F, Bao J, Pang Y, Pershad R, Issa JP, Liao WS, Bast RJ, Yu Y:
Genomic structure and promoter characterization of an imprinted tumor
suppressor gene ARHI. Biochim Biophys Acta 2001, 1519:216–222.
51. Kawazu M, Saso K, Tong KI, McQuire T, Goto K, Son DO, Wakeham A,
Miyagishi M, Mak TW, Okada H: Histone demethylase JMJD2B functions as
a co-factor of estrogen receptor in breast cancer proliferation and
mammary gland development. PLoS One 2011, 6:e17830.
52. Kouzarides T: Histone acetylases and deacetylases in cell proliferation.
Curr Opin Genet Dev 1999, 9:40–48.
53. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL:
Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624–1633.
54. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis.
Nat Rev Cancer 2009, 9:239–252.
55. Langley RR, Fidler IJ: The seed and soil hypothesis revisited–the role of
tumor-stroma interactions in metastasis to different organs. Int J Cancer
2011, 128:2527–2535.
56. Mook OR, van Marle J, Jonges R, Vreeling-Sindelarova H, Frederiks WM, Van
Noorden CJ: Interactions between colon cancer cells and hepatocytes in
rats in relation to metastasis. J Cell Mol Med 2008, 12:2052–2061.
57. Mook OR, Van Marle J, Vreeling-Sindelarova H, Jonges R, Frederiks WM,
Van Noorden CJ: Visualization of early events in tumor formation of
eGFP-transfected rat colon cancer cells in liver. Hepatology 2003,
38:295–304.
58. Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C,
Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C,
Adam R, Hallett M, Siegel PM: Claudin-2 is selectively enriched in and
promotes the formation of breast cancer liver metastases through
engagement of integrin complexes. Oncogene 2011, 30:1318–1328.
59. Tabaries S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE,
Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM: Claudin-2 promotes
breast cancer liver metastasis by facilitating tumor cell interactions with
hepatocytes. Mol Cell Biol 2012, 32:2979–2991.
doi:10.1186/bcr3667
Cite this article as: Li et al.: JMJD2A contributes to breast cancer
progression through transcriptional repression of the tumor suppressor
ARHI. Breast Cancer Research 2014 16:R56.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
